SnagRx vs IVIM Health: Pricing, Protocols, and Patient Signals
Short verdict: For lowest annual compounded GLP-1 pricing and a lifetime price lock, SnagRx leads; for third-party ratings and a structured optimization protocol, IVIM Health stands out. This quick SnagRx vs IVIM Health comparison focuses on pricing structure, clinical program and outcomes claims, independent satisfaction signals, and fulfillment details.
See SnagRx pricing and enrollment
Key differences at a glance
Compare the most distinctive differences supported by the sources: plan pricing and commitment, clinician protocol and outcome claims, external ratings and verification, and pharmacy/shipping details. Each item below references supplied facts only.
1. Pricing model and commitment
SnagRx advertises compounded semaglutide from $69/month and tirzepatide from $119/month as 12-month plan rates; month-to-month rates are $99 and $149. SnagRx states the 12-month figures are the plan rates and that the rate is locked flat at every dose for the life of treatment.
IVIM Health lists semaglutide at $75/month and tirzepatide at $133/month on its landing content, and describes an ongoing price that markets show as $174/month after initial pricing. IVIM also advertises a free month membership with code GIFT75 and a no-obligation free consultation valued at $75.
2. Program design and outcome claims
SnagRx is presented as a direct-pay telehealth platform delivering compounded GLP-1 medications with telemed clinician review via the OpenLoop Health network. SnagRx notes clinician review typically within five hours and next-day shipping for approved orders. SnagRx publishes that OpenLoop Health clinicians determine eligibility and that compounded medications are not FDA-approved finished products.
IVIM Health promotes a proprietary GLP-1 ID protocol and states that, based on its published study, IVIM patients following the protocol lost an average of 46% more weight over 68 weeks compared to another published clinical GLP-1 trial. The source qualifies that this is not a head-to-head study and that the 40% or 46% figures are protocol or internal claims, not independent randomized trials.
3. Third-party validation and trust signals
SnagRx states it holds LegitScript certification and names its four US 503A partner pharmacies and the OpenLoop Health clinician network. IVIM Health highlights unusually strong third-party satisfaction signals, claiming 4.9-star ratings on both Google and Trustpilot, which the source presents as a rare dual verification in this market.
4. Fulfillment and pharmacy details
SnagRx names its partner US 503A compounding pharmacies, says orders ship next-day via UPS or FedEx in temperature-controlled packaging, and discloses that compounded medications are produced in FDA-regulated facilities but are not FDA-approved products.
IVIM states its medications are prepared by independent, licensed compounding pharmacies, notes compounded drugs are not FDA-approved, and indicates not all services are available in every state.
Comparison table
| Criteria | SnagRx | IVIM Health |
|---|---|---|
| Starting price (compounded semaglutide) | $69/mo on 12-month plan; $99 mo-to-mo | $75/mo listed; ongoing pricing noted around $174/month |
| Price commitment | 12-month plan required to get $69; price locked at every dose | Free month with code GIFT75; initial offers then higher ongoing rate |
| Clinical protocol | Telehealth clinician review via OpenLoop Health; clinician decides eligibility | Proprietary GLP-1 ID protocol claiming faster outcomes; internal study cited |
| Third-party verification | States LegitScript certification and named partner pharmacies | 4.9-star ratings on Google and Trustpilot listed |
| Medication type and regulatory note | Compounded GLP-1s; not FDA-approved finished products | Compounded GLP-1s; not FDA-approved finished products |
| Fulfillment speed | Typical clinician review within 5 hours; next-day shipping for approved orders | Medications from licensed compounding pharmacies; availability varies by state |
How these differences matter
Cost sensitive patients who want the lowest annual compounded price and predictability across titration may prefer SnagRx because the $69 and $119 figures are the 12-month plan rates and SnagRx emphasizes a lifetime price lock at every dose. The SnagRx source also highlights named US 503A pharmacies, OpenLoop clinician review timing, and next-day shipping for approved orders.
Patients who prioritize independent verification and a structured clinical program may favor IVIM Health. IVIM emphasizes dual 4.9-star ratings on Google and Trustpilot and markets a proprietary GLP-1 ID protocol with internal study results. IVIM additionally offers a free consultation valued at $75 and a free-month-membership code to reduce upfront cost.
Explore IVIM Health program details
Safety and regulatory notes
Both sources clearly state their GLP-1 products are compounded medications and are not FDA-approved finished products. SnagRx and IVIM each note that compounded drugs have not undergone FDA review for safety, efficacy, or quality and that clinician judgment determines prescription eligibility.
Conclusion: Choose based on priorities
SnagRx vs IVIM Health boils down to whether you prioritize lowest annual compounded pricing with a price-lock and named pharmacies, or independent satisfaction signals and a proprietary clinician-guided protocol. Both use compounded GLP-1s and operate as direct-pay telehealth services.
Choose SnagRx if you want the 12-month plan pricing and a flat rate across titration, named US 503A pharmacies, and stated fast clinician review and next-day shipping. Choose IVIM Health if third-party ratings and a structured GLP-1 ID protocol with a free consultation and free-month offer matter more to you.